Clearside Biomedical Receives Hold Rating Amid Financial Uncertainty and Strategic Exploration

JonesTrading analyst Debanjana Chatterjee has maintained a neutral stance on CLSD stock with a Hold rating due to the company's financial uncertainty and strategic exploration. Clearside Biomedical has a cash reserve of $9.4 million, which is set to decrease further, and is exploring strategic alternatives while all research and development activities are on hold. The outcome and timing of any strategic transaction are uncertain, leading to the decision to maintain a Hold rating.

Clearside Biomedical Inc (CLSD) is set to report its quarterly earnings on August 11, 2025, with analysts expecting a significant rise in revenue. According to LSEG data, the company is anticipated to report an 88.9% increase in revenue to $170,000 from $90,000 a year ago. However, the company is also expected to post a loss of 10 cents per share, reflecting ongoing financial challenges [1].

The Alpharetta, Georgia-based company has a current average analyst rating of "hold," with 6 analysts recommending a hold rating and no analysts recommending a "sell" or "strong sell." The median 12-month price target for CLSD is $5.00, about 92.3% above its last closing price of $0.38 [1].

Financial analysts have highlighted the company's acute liquidity pressure and going-concern disclosure. Clearside Biomedical has a cash reserve of $9.4 million, which is expected to decrease further. The company has paused its research and development activities and is exploring strategic alternatives while facing significant operational losses and workforce reductions [2].

The company's balance sheet shows a cash reserve of $9.4 million against significant obligations, including a $55.7 million royalty liability. Operating cash used was $10.6 million over six months, and the company posted a $12.7 million net loss for the first half of 2025. While license milestones added $2.8 million of revenue, the combination of low cash, a going-concern statement, Nasdaq noncompliance, and workforce reductions materially increases financing and execution risk [2].

JonesTrading analyst Debanjana Chatterjee has maintained a neutral stance on CLSD stock with a Hold rating due to the company's financial uncertainty and strategic exploration. The outcome and timing of any strategic transaction are uncertain, leading to the decision to maintain a Hold rating [2].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U0201:0-clearside-biomedical-inc-expected-to-post-a-loss-of-10-cents-a-share-earnings-preview/
[2] https://www.stocktitan.net/sec-filings/CLSD/10-q-clearside-biomedical-inc-quarterly-earnings-report-3a85fb037cac.html